Press Releases
Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology
Palleon Pharmaceuticals Appoints Denis Patrick to its Board of Directors
Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity
Palleon Pharmaceuticals Appoints David Johnson to its Board of Directors
In the News
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury
Palleon battalion bags $100M series B for glycan push
BioWorld
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints
Social Media
Our #PalleonPeople started with a passion for scientific discovery. See why they chose to enter this life-changing… http://VpEZOoiuyK
Today we announced FDA clearance of the IND application for our lead candidate, E-602, Palleon’s first glyco-immuno… http://LjU0SuHTGz